Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value

Histopathology

Volumn 60, Issue 2, 2012, Pages 278-286

  Wachter, David L ^a   Kristiansen, Glen ^b   Soll, Christopher ^b   Hellerbrand, Claus ^c   Breuhahn, Kai ^d   Fritzsche, Florian ^b   Agaimy, Abbas ^a   Hartmann, Arndt ^a   Riener, Marc Oliver ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Hepatocellular carcinoma; Immunohistochemistry; Insulin like growth factor II mRNA binding protein 3

Indexed keywords

CD34 ANTIBODY; GLYPICAN 3; INSULIN LIKE GROWTH FACTOR II MRNA BINDING PROTEIN 3; ONCOFETAL ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FOCAL NODULAR HYPERPLASIA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SCHOOL CHILD;

ADENOMA, LIVER CELL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BIOPSY, NEEDLE; CARCINOMA, HEPATOCELLULAR; CHILD; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOCAL NODULAR HYPERPLASIA; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYPICANS; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; RNA-BINDING PROTEINS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84255204433     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04091.x     Document Type: Article

References (38)

1. Goodman ZD, Terracciano LM. Tumours and tumour-like lesions of the liver. In Burt AD, Portmann BC, Ferrell LD eds. MacSween's pathology of the liver. Philadelphia: Churchill Livingstone, 2007; 761-814.
2. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann. Intern. Med. 2003; 139; 817-823.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42; 1208-1236.
4. Anatelli F, Chuang ST, Yang XJ, Wang HL. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am. J. Clin. Pathol. 2008; 130; 219-223.
5. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4, 387 tissue samples. Am. J. Clin. Pathol. 2008; 129; 899-906.
6. Lefkowitch JH. Recent developments in liver pathology. Hum. Pathol. 2009; 40; 445-455.
7. Ruck P, Xiao JC, Kaiserling E. QBend 10 (CD34) in the diagnosis of hepatocellular carcinoma. Histopathology 1996; 29; 593-594.
8. Varma V, Cohen C. Immunohistochemical and molecular markers in the diagnosis of hepatocellular carcinoma. Adv. Anat. Pathol. 2004; 11; 239-249.
9. Wang HL, Anatelli F, Zhai QJ, Adley B, Chuang ST, Yang XJ. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch. Pathol. Lab. Med. 2008; 132; 1723-1728.
10. Coston WM, Loera S, Lau SK et al. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am. J. Surg. Pathol. 2008; 32; 433-444.
11. Hoffmann NE, Sheinin Y, Lohse CM et al. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 2008; 112; 1471-1479.
12. Jiang Z, Lohse CM, Chu PG et al. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 2008; 112; 2676-2682.
13. Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod. Pathol. 2007; 20; 242-247.
14. Li C, Zota V, Woda BA et al. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod. Pathol. 2007; 20; 1263-1268.
15. Lu D, Vohra P, Chu PG, Woda B, Rock KL, Jiang Z. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia. Am. J. Surg. Pathol. 2009; 33; 521-525.
16. Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H. IMP-3 is a novel progression marker in malignant melanoma. Mod. Pathol. 2008; 21; 431-437.
17. Pryor JG, Simon RA, Bourne PA, Spaulding BO, Scott GA, Xu H. Merkel cell carcinoma expresses K homology domain-containing protein overexpressed in cancer similar to other high-grade neuroendocrine carcinomas. Hum. Pathol. 2009; 40; 238-243.
18. Sitnikova L, Mendese G, Liu Q et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin. Cancer Res. 2008; 14; 1701-1706.
19. Xu H, Bourne PA, Spaulding BO, Wang HL. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum. Pathol. 2007; 38; 555-563.
20. Yantiss RK, Woda BA, Fanger GR et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am. J. Surg. Pathol. 2005; 29; 188-195.
21. Zhao H, Mandich D, Cartun RW, Ligato S. Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas. Diagn. Cytopathol. 2007; 35; 700-704.
22. Zheng W, Yi X, Fadare O et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am. J. Surg. Pathol. 2008; 32; 304-315.
23. Riener MO, Fritzsche FR, Clavien PA et al. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. Hum. Pathol. 2009; 40; 1377-1383.
24. Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum. Pathol. 2009; 40; 1528-1533.
25. Jeng YM, Chang CC, Hu FC et al. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology 2008; 48; 1118-1127.
26. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132; 2557-2576.
27. Riener MO, Bawohl M, Clavien PA, Jochum W. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosom. Cancer 2008; 47; 363-367.
28. Monk D, Bentley L, Beechey C et al. Characterisation of the growth regulating gene IMP3, a candidate for Silver-Russell syndrome. J. Med. Genet. 2002; 39; 575-581.
29. Mueller-Pillasch F, Lacher U, Wallrapp C et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997; 14; 2729-2733.
30. Nielsen FC, Nielsen J, Christiansen J. A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand. J. Clin. Lab. Invest. Suppl. 2001; 234; 93-99.
31. Mueller-Pillasch F, Pohl B, Wilda M et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech. Dev. 1999; 88; 95-99.
32. Nielsen J, Adolph SK, Rajpert-De Meyts E et al. Nuclear transit of human zipcode-binding protein IMP1. Biochem. J. 2003; 376; 383-391.
33. Liao B, Hu Y, Herrick DJ, Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J. Biol. Chem. 2005; 280; 18517-18524.
34. Vikesaa J, Hansen TV, Jonson L et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J. 2006; 25; 1456-1468.
35. Mhawech-Fauceglia P, Herrmann FR, Rai H et al. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am. J. Clin. Pathol. 2010; 133; 899-908.
36. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997; 57; 5179-5184.
37. Sauter G. Representativity of TMA studies. Methods Mol. Biol. 2010; 664; 27-35.
38. Nemunaitis J, Meyers T, Senzer N et al. Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol. Ther. 2006; 13; 1185-1191.